Key Developments

On March 7, 2024, Bristol Myers Squibb, a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common form of bladder cancer.
On January 25, 2024, Alphamab Oncology, a clinical-stage biopharmaceutical company, and 3DMedicines, a leading innovative biopharmaceutical company, announced that they have entered into a license agreement with Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd., a pharmaceutical company, for the subcutaneous injection PD-L1 antibody drug, pursuant to which Glenmark was granted exclusive licensing interests in clinical development and commercialization of oncology in India, Asia Pacific (except Singapore, Thailand, and Malaysia), the Middle East and Africa, Russia, CIS, and Latin America.
On January 12, 2024, Merck & Co., Inc., a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT), for the treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage III-IVA cervical cancer.
On January 8, 2024, Johnson & Johnson, a healthcare company, announced that it has signed a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx, a clinical-stage biopharmaceutical company that uses a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs). Ambrx is advancing a focused portfolio of clinical and preclinical initiatives designed to maximize the efficacy and safety of its potential candidate in several cancer indications.